All AbMole products are for research use only, cannot be used for human consumption.

AG-014699 (PF-01367338, Rucaparib) is a PARP inhibitor with a Ki of 1.4 nM. AG-014699 is the phosphate salt of AG 014447 (CAS 283173-50-2) and has improved aqueous solubility. Poly (ADP-ribose) polymerases (PARPs) are activated by DNA single- and double-strand breaks and promote repair of DNA damage through the relaxation of chromatin and recruitment of other repair proteins. AG-014699 inactivates PARP activity in cells with homologous recombination DNA repair pathway mutations at LC50 values ranging from 1.3-5.5 μM. Radio-sensitization by AG-014699 is due to downstream inhibition of NF-κB activation, and independent of SSB repair inhibition. Although AG014699 can enhance response to some chemotherapeutic drugs via improved delivery, this does not apply to doxorubicin. PARP inhibitors may still be of use to counter doxorubicin toxicity.
| Cell Experiment | |
|---|---|
| Cell lines | LoVo and SW620 cells |
| Preparation method | We estimated cell growth inhibition in exponentially growing LoVo and SW620 cells in 96-well plates exposed to increasing concentrations of single-agent PARP inhibitor, temozolomide or topotecan, or combinations of temozolomide or topotecan with PARP inhibitor for 5 days before staining with sulforhodamine B as described previously (18). Cell growth, determined after subtraction of time 0 values, was expressed as a percentage of the relevant DMSO, cytotoxic drug, or PARP inhibitor alone control, as appropriate. GI50 (concentration of drug that inhibited growth by 50%) values were calculated from the computer-generated curves (GraphPad Software, Inc. San Diego CA). |
| Concentrations | 0~1000µM |
| Incubation time | 5 days |
| Animal Experiment | |
|---|---|
| Animal models | SW620 tumor xenografts |
| Formulation | saline |
| Dosages | 0.1, 1, 10mg/kg |
| Administration | oral |
| Molecular Weight | 421.36 |
| Formula | C19H18FN3O.H3PO4 |
| CAS Number | 459868-92-9 |
| Solubility (25°C) | DMSO ≥30 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[3] Hunter et al. Oncogene. NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699.
| Related PARP Products |
|---|
| ABT-888
ABT-888 (Veliparib) is a potent inhibitor of PARP-1 and PARP-2 with Ki values of 5.2nM and 2.9nM respectively. |
| AG14361
AG14361 is a novel poly (ADP-ribose) polymerase-1 inhibitor with a GI50 of 10.9 µM. |
| AZD2281 (Olaparib)
AZD 2281 (Olaparib, KU-0059436) is a potent PARP (poly ADP-ribose polymerase) inhibitorwith IC50 of 5 and 1 nM for PARP-1and PARP-2 respectively. Olaparib is an autophagy and mitophagy activator. |
| Talazoparib
Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity. |
| 3-Aminobenzamide
3-Aminobenzamide (PARP-IN-1) is a novel poly(ADP-ribose) polymerase (PARP) inhibitor, and it inhibits cell apoptosis after SCI (Spinal Cord Injury) in caspase-independent way. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
